M
Mark A. Schnitzler
Researcher at Saint Louis University
Publications - 268
Citations - 14664
Mark A. Schnitzler is an academic researcher from Saint Louis University. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 61, co-authored 254 publications receiving 13236 citations. Previous affiliations of Mark A. Schnitzler include Washington University in St. Louis & Barnes-Jewish Hospital.
Papers
More filters
Journal ArticleDOI
Diabetes mellitus after kidney transplantation in the United States.
TL;DR: The authors’ analysis of risk factors for new-onset diabetes and its clinical implications provides valuable evidence on this important issue, and highlights the need for management strategies that minimize risk of diabetes developing after transplantation.
Journal ArticleDOI
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.
Daniel C. Brennan,Irfan Agha,Daniel L. Bohl,Mark A. Schnitzler,Karen L. Hardinger,Mark B. Lockwood,Stephanie Torrence,Rebecca Schuessler,Tiffany Roby,Monique Gaudreault-Keener,Gregory A. Storch +10 more
TL;DR: Whether intensive monitoring and discontinuation of mycophenolate (MMF) or azathioprine (AZA), upon detection of BK viremia, could prevent BK nephropathy with tacrolimus (FK506) versus cyclosporine (CyA) is investigated.
Journal ArticleDOI
OPTN/SRTR 2012 Annual Data Report: kidney.
Arthur J. Matas,Jodi M. Smith,Melissa Skeans,Bryn Thompson,Sally K. Gustafson,Mark A. Schnitzler,Darren Stewart,Wida S. Cherikh,J. L. Wainright,Jon J. Snyder,Ajay K. Israni,Bertram L. Kasiske +11 more
TL;DR: Kidney transplant is one of the most cost‐effective surgical interventions; however, average reimbursement for recipients with primary Medicare coverage from transplant through 1 year posttransplant was comparable to the 1‐year cost of care for a dialysis patient.
Journal ArticleDOI
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients.
Robert S. Woodward,Mark A. Schnitzler,Jack Baty,Jeffrey A. Lowell,Lissa Lopez-Rocafort,Seema Haider,Thasia G. Woodworth,Daniel C. Brennan +7 more
TL;DR: While NodM had an incidence of approximately 6% per year among wait‐listed dialysis patients, NODM over the first 2 years post‐transplant had an occurrence of almost 18% and 30% among patients receiving cyclosporine and tacrolimus, respectively.
Journal ArticleDOI
A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients
Daniel C. Brennan,Karen Flavin,Jeffrey A. Lowell,Todd K. Howard,Surendra Shenoy,S Burgess,Sara Dolan,Jennifer M. Kano,Mitchell Mahon,Mark A. Schnitzler,Robert S. Woodward,William Irish,Gary G. Singer +12 more
TL;DR: Brief (7-day) induction with Thymoglobulin resulted in less frequent and less severe rejection, a better event-free survival, less cytomegalovirus disease, fewer serious adverse events, but more frequent early leukopenia than induction with Atgam.